Approximately 80 % of GIST patients have a mutation in c-kit, and 10 % harbor a mutation in PDGFRA. Therefore, development of TKIs of imatinib, sunitinib, and regorafenib targeting both KIT and PDGFRA tyrosine kinases is being vigorously advanced. This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.